Nasal human calcitonin for tumor-induced hypercalcemia.
We treated four hypercalcemic cancer patients by nasal hCT, 3 x 2 mg daily, which has been reported to be active in Paget's disease at lower doses. Only one patient became normocalcemic and mean (+/- SEM) calcium levels fell from 11.6 +/- 0.2 mg/dl before therapy to 10.7 +/- 0.6 mg/dl 2-3 days after starting hCT. The tolerance was excellent but, because of insufficient efficacy, we do not recommend this form of therapy for cancer hypercalcemia.
Dumon
J C
JC
Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Belgium.
Magritte
A
A
Body
J J
JJ
D000230:Adenocarcinoma / Q000097:blood / Q000150:complications*; D000281:Administration, Intranasal; D000368:Aged; D002116:Calcitonin / Q000008:administration & dosage / Q000592:standards / Q000627:therapeutic use*; D002118:Calcium / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology*; D008175:Lung Neoplasms / Q000097:blood / Q000150:complications*; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000097:blood
D010710:Phosphates; D002116:Calcitonin; D002118:Calcium